Home › Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study
 

Keywords :   


Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

2014-10-10 04:59:10| Biotech - Topix.net

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy . "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.

Tags: study million advance phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Atlantic Tropical Weather Outlook
30.09Eastern North Pacific Tropical Weather Outlook
30.09Does Chinese investment benefit or damage Ireland?
29.09Tropical Depression Twelve Public Advisory Number 1
29.09Summary for Tropical Depression Twelve (AT2/AL122024)
29.09Tropical Depression Twelve Wind Speed Probabilities Number 1
29.09Tropical Storm Joyce Forecast Discussion Number 10
29.09Tropical Depression Twelve Forecast Discussion Number 1
More »